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Background: Linifanib (ABT-869) is an orally active receptor tyrosine kinase inhibitor, which simultaneously inhibits
vascular endothelial and platelet derived growth factor receptor. The aim of the present study was to develop
an UHPLC-MS/MS method for the quantification of linifanib in rat plasma to support the pharmacokinetic and
toxicokinetic studies.
Results: Linifanib was separated on Acquity UPLC BEH™ C18 column (50 × 2.1 mm, i.d. 1.7 μm) using
acetonitrile-10 mM ammonium acetate (60:40, v/v) as an isocratic mobile phase at a flow rate of 0.3 mL/min with
sunitinib as internal standard (IS). Detection was performed on tandem mass spectrometer using electrospray
ionization source in positive mode by multiple reaction monitoring. The monitored transitions were set at m/z
376.05 > 250.97 for linifanib and m/z 399.12 >283.02 for IS, respectively. Both linifanib and IS were eluted at 0.68
and 0.44 min, respectively with a total run time of 2.0 min only. The calibration curve was found to be linear over
the concentration range of 0.40–500 ng/mL. The intra- and inter-day precision value was ≤10.6% and the accuracy
ranged from 90.9-108.9%. In addition, all the validation results were within general assay acceptability criteria according
to guidelines of bio-analytical method validation.
Conclusion: A selective and sensitive UHPLC-MS/MS method was developed and validated for the determination of
linifanib in rat plasma for the first time. The developed method is simple, sensitive and rapid in terms of chromatographic
separation and sample preparation and was successfully applied in a pilot pharmacokinetic study in rats.
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Vascular endothelial and platelet derived growth factor
receptor (VEGFR and PDGFR) plays a major role in
angiogenesis and tumor cell proliferation. It has been
reported that the simultaneous inhibition of these two
receptors achieves greater antitumor activities than in-
hibition of either receptor alone [1,2]. Linifanib (ABT-
869) is an orally active novel small molecule multi-target
receptor tyrosine kinase (RTK) inhibitor, which simul-
taneously inhibits VEGFR and PDGFR with minimal
activity against unrelated RTKs. It has potent inhibitory
activity against VEGFR-1, VEGFR-2, PDGFRb, colony-* Correspondence: muziqbal@gmail.com
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unless otherwise stated.stimulating factor 1 receptor, and fms-related tyrosine
kinase 3, with minimal activity against unrelated tyrosine
and serine/threonine kinases [3-5]. Linifanib has shown
prominent antitumor activity against solid tumors in
phase 2 studies e.g. non-small cell lung cancer, hepato-
cellular carcinoma and renal cell carcinoma [6-9] and
presently are in phase 3 studies in patients with hepato-
cellular carcinoma [9].
Based on the available preliminary phase I study data,
the pharmacokinetics of linifanib was dose proportional
and time invariant. It was rapidly absorbed with peak
plasma concentration achieved in approx. 2 h across all
dose levels. The oral clearance was 2.7 L/h, and the main
systemic metabolite was the carboxylate metabolite and
only 15% of the dose was recovered as unchanged in
urine [10,11].l Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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drug, a selective and sensitive bioanalytical method is
required for its pharmacokinetic and toxicokinetic studies.
The chromatographic separation procedure of reported
LC-MS/MS method (for linifanib and its acid metabolite)
in plasma requires pre-column back wash and takes more
than 6 min to complete the one sample analysis [12].
Though its extraction procedure was based on automated
liquid liquid extraction (high-throughput), but mean
extraction recovery was only 18% and it also required
Hamilton automated liquid handler with 96 well plates
for operation. Wu H et al 2008, used salting-out assisted
liquid/liquid extraction procedure, but the recovery
couldn’t exceeded of 40% [13]. Amongst the available
analytical techniques, UHPLC has gained a considerable
attention due to use of Acquity BEH column, which not
only increased the separation throughput and efficiency
but also reduced the retention time and volume of solvent
required during separation [14-16]. The aim of the present
study was to develop a sensitive UHPLC-MS/MS method,
which can facilitate the rapid determination of linifanib




Linifanib (purity ≥98%) was purchased from Weihua
Pharma Co., Limited, Zhejiang, China and sunitinib mal-
ate (internal standard; purity ≥98%) was purchased from
Sigma-Aldrich, USA (Figure 1). Methanol and acetonitrile
were of HPLC grade obtained from Winlab Laboratory,
whereas formic acid and ammonium acetate were of ana-
lytical grade obtained from BDH Laboratory, England. All
aqueous solutions used in this study were obtained from
Milli-QR Gradient A10R (Millipore, Moscheim Cedex,
France) having pore size 0.22 μm. Blank rat plasma was
separated from the healthy rats which obtained from the
Animal Care and Use Centre, College of Pharmacy, King
Saud University, Riyadh, Saudi Arabia.
Preparation of stock solutions, calibration standards and
quality control samples
Standard stock solutions of 1.0 mg/mL were prepared
for linifanib in methanol and sunitinib (IS) in dimethyl
sulphoxide by dissolving the accurate amounts of their
reference standards. A series of working standard solu-
tions of linifanib were prepared by further dilution of
the stock solution using acetonitrile. All stock solutions
and working solutions were kept in refrigerator at 4°C.
Plasma calibration standards were prepared by spiking
the appropriate amounts of the working standard solu-
tions into blank plasma to obtain final concentration
levels of 0.40, 1.13, 3.24, 10.80, 36.0, 120, 300 and
500 ng/mL. Quality control (QC) samples at fourdifferent concentrations: 0.45, 1.28, 42.50 and 425 ng/mL
in blank rat plasma were also prepared in a similar
manner and treated as LOQ QC, LQC, MQC and HQC
respectively. Both plasma calibration standards and QC
samples were kept at −80°C until used during validation
and/or sample analysis. The IS working solution (1 μg/mL)
for routine use was prepared by diluting the IS stock
solution in acetonitrile and were stored at 4°C.
UHPLC separation and MS/MS parameters
The equipment consisted of ACQUITY™ UHPLC system
coupled to triple-quadruple tandem mass spectrometer
(Waters Corp., Milford, MA, USA). The UHPLC system
consisted of quaternary solvent manager, a binary pump,
degasser, autosampler with an injection loop of 10 μL
and a column heater-cooler. The chromatographic sep-
aration was performed on Acquity BEH™ C18 column
(50 × 2.1 mm, i.d., 1.7 μm, Waters, USA) maintained at
ambient temperature. The mobile phase was comprised
of acetonitrile:10 mM ammonium acetate (60:40, v/v)
at a flow rate of 0.3 mL/min. Linifanib and IS were
eluted at 0.68 and 0.44 min respectively with a total
run time of 2.0 min only. The injection volume was
5 μL in partial loop mode and the temperature of the
autosampler was 10°C.
Triple-quadruple tandem mass spectrometer equipped
with electrospray ionization (ESI) interface was used for
analytical detection. The detection was obtained in ESI
positive mode using multiple reaction monitoring (MRM),
with transition channels of proton molecular ions was
m/z 376.05 > 250.97 for linifanib and m/z 399.12 >283.02
for IS, having dwell time of 0.106 s. Nitrogen was used as
a desolvating gas at a flow rate of 600 L/h. The desolvating
temperature was 350°C whereas source temperature was
150°C. The collision gas (argon) flow was 0.1 mL/min and
capillary voltage was set at 3.5 kV. The compound pa-
rameters like cone voltage and collision energy were set
at 46 V & 30 eV for linifanib and 36 V & 22 eV for IS
respectively. The Mass Lynx software (Version 4.1, SCN
714) was used to control the UHPLC-MS/MS system
and data was collected and processed using Target
Lynx™ program.
Sample preparation
Plasma samples stored at around −80°C were thawed,
left for 1 h at room temperature and vortexed for 30 sec
before extraction. In a fresh 1.5 mL centrifuge tube,
200 μL plasma (calibration standards, QCs and unknown
samples) followed by 20 μL of IS (1 μg/mL) was added.
The sample was vortexed for 30 sec and again by
addition of 15 μL of formic acid to each tube. After
vortexed, 445 μL of acetonitrile was added and again
vortexed gently for 2 min, then centrifuged for 8 min at
12500 rpm at 4°C. After centrifugation, supernatant
Linifanib Sunitinib
Figure 1 Chemical structure of linifanib and sunitinib.
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under a stream of nitrogen at approximately 40°C. The
residue was reconstituted in 200 μL of the mobile phase,
vortexed for 30 sec and 5 μL was injected into UPLC–
MS/MS for analysis.Figure 2 MS spectra of linifanib (A) and IS (B) and MS/MS spectra of lMethod validation
A full method validation was performed according to
guidelines set by the United States Food and Drug
Administration and European Medicines Agency [17,18].
The developed method was validated in terms of selectivity,inifanib (C) and IS (D).
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effects, dilution integrity and stability of the analytes during
both short-term sample processing and long-term storage.
Method selectivity was investigated by the comparison
of chromatograms of blank plasma obtained from differ-
ent healthy rats with the corresponding chromatograms
of plasma samples spiked at LLOQ (0.40 ng/mL) level of
the analyte and 100 ng/ml of the IS.
The linearity of the method was determined by per-
forming the three calibration curves with eight different
concentrations ranging from 0.40-500 ng/mL. The cor-
relation coefficient r2 > 0.995 was desirable for all the
calibration curves. The peak area ratios of the analyte to
IS were calculated and the calibration curves were estab-
lished by fitting these ratios to the corresponding con-
centrations using weighted least square linear regression.
The lowest concentration of the analyte (0.40 ng/mL)
on the calibration curve was considered as LLOQ with
acceptable accuracy and precision.
The precision of the assay is expressed as percentage co-
efficient of variation (% CV), whereas accuracy is expressed
as a percentage deviation from the respective nominalFigure 3 Representative MRM chromatograms of linifanib and IS in (A
oral administration of linifanib 5 mg/kg in rat.value. For precision and accuracy, QC samples at four
different concentration levels (LOQ QC, LQC, MQC and
HQC) were analyzed in six replicates on the same day
(intra-day) and on three different days (inter-day) re-
spectively. The deviation in mean value of precision
should not exceed 20% for the lowest QC samples and
15% for the other QC samples and accuracy should be
within ±20% for the lowest QC samples and ±15% for
the other QC samples.
The extraction recovery of linifanib at three QC levels
and IS at 100 ng/mL were evaluated by comparing peak
area ratios of plasma spiked with analyte prior to extrac-
tion with the peak area ratios of plasma spiked with ana-
lyte after the extraction. Calculation of the matrix effects
was conducted by calculating the peak area ratio of
extracted rat plasma post spiked with analyte to the peak
area of the analyte in reconstitution solution in the same
concentration. Deviation in linifanib and IS concentra-
tions of a maximum of 15%were considered acceptable
as recommended in EMEA bioanalytical guideline [18].
The stability of linifanib in rat plasma during the sam-
ple storage and processing conditions was assessed by) blank plasma; (B) plasma spiked at LLOQ level and (C) 1 h after
Table 1 Intraday and interday precision and accuracy of linifanib in rat plasma
Nominal concentration (ng/mL) Run Rat plasma
Mean ± SD Precision (% CV) Accuracy (%)
Intraday variation (six replicate at each concentration)
0.45 1 0.48 ± 0.05 10.4 107.0
2 0.47 ± 0.05 10.6 104.4
3 0.49 ± 0.05 10.2 108.9
1.28 1 1.35 ± 0.14 10.4 105.3
2 1.38 ± 0.14 10.1 105.0
3 1.35 ± 0.08 5.9 105.6
42.5 1 44.5 ± 3.28 7.4 104.6
2 39.7 ± 3.58 9.0 93.5
3 40.2 ± 1.56 3.9 94.6
425 1 397 ± 36.4 9.2 93.5
2 387 ± 12.2 3.2 90.9
3 398 ± 13.5 3.4 93.9
Interday variation (18 replicates at each concentration)
0.45 0.48 ± 0.05 10.4 106.8
1.28 1.36 ± 0.09 6.6 106.3
42.5 41.48 ± 3.53 8.5 97.6
425 394 ± 22.79 5.8 92.8
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stability was assessed after keeping the plasma samples
at ambient temperature for ∼ 6 h, the freeze–thaw sta-
bility was determined after three cycles of freeze-thaw.
Post-preparative stability was determined by storing the
reconstituted QC samples for ∼ 48 h under autosampler
conditions (maintained at 10°C) before being analyzed.
Long-term stability was assessed after storage of the
test samples at around −80°C for 30 days. The working
solutions and stock solutions of linifanib and the IS
were also evaluated for stability at room temperature
for 12 h and at refrigerator temperature (below 10°C)
for 15 days. The samples were considered stable in plasma
at each concentration if the deviation from the mean
calculated concentration of quality control samples were
within ±15%.
Dilution integrity was evaluated to ensure the integrity
of analyte in those samples which were beyond upper





Sunitinib (IS) 100.0fresh stock of linifanib was prepared and spiked in
plasma to get a concentration level of 1.8 times of high-
est standard of the usual calibration standard, and then
diluted 2 and 4 times with the same plasma. Six aliquots
of both dilutions were processed along with freshly spiked
calibration standards and analyzed by back calculation
using regression equation obtained. The integrity of the
samples were considered to be maintained if percentage
nominal is within ± 15% of nominal values and % CVs ≤ 15%
at both diluted levels.
Application to pharmacokinetic interaction study in rats
To demonstrate the utility of this method, a pilot phar-
macokinetic study of linifanib was performed in six male
wistar albino rats weighting from 220 to 230 g. After an
overnight fasting, all rats received linifanib (5 mg/kg,
oral, dissolved in HPMC). Blood samples (approximately
0.5 mL) were collected from the retro-orbital plexus into
heparinized microfuge tubes at different time intervalin rat plasma (Mean ±SD)






Table 3 Stability and dilution integrity data of linifanib in rat plasma
Stability Nominal concentration (ng/mL) (n = 6) Mean ± SD Precision (% CV) Accuracy (%)
Bench top (6 hrs) 1.28 1.35 ± 0.06 4.4 105.0
425 393 ± 34.8 8.9 92.7
Freeze thaw (3 cycle) 1.28 1.30 ± 0.10 7.7 101.1
425 385 ± 14.3 3.7 90.7
In injector (48 hrs) 1.28 1.42 ± 0.09 6.3 110.6
425 455 ± 19.8 4.4 107.2
30 days at −80°C 1.28 1.26 ± 0.10 7.9 98.3
425 384 ± 20.2 5.3 90.5
Dilution integrity 225 226 ± 16.4 7.3 100.7




























Figure 4 Mean ± SD plasma concentration- time curves of linifanib
after a single oral dose of 5 mg/kg in rats.
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harvested by centrifuging the blood at 4500 rpm for
8 min and stored frozen at −80 ± 10°C until analysis. The
pharmacokinetic parameters: Cmax, Tmax, AUC, t½ and Kel
were calculated using WinNonlin software.
Result and discussion
Method development
Optimization of mass spectroscopy condition
Expecting high selectivity and sensitivity of the MS/MS
detection, operation parameters were carefully optimized
before detection by MRM mode. Initially, linifanib and
IS response were evaluated by directly infusing into the
mass spectrometer for tuning in both positive and nega-
tive ESI mode. It was observed that the signal intensity
of positive ion (ESI+) was much higher than that of
negative ion for both analyte and IS. Parameters, such as
capillary and cone voltage, desolvation temperature, ESI
source temperature and flow rate of desolvation gas and
cone gas were optimized to obtain the optimum inten-
sity of protonated molecular ions (M+ H)+ for linifanib
and IS. Linifanib produced the maximum intensity of
daughter ion signals when cone voltage and collision
energy was set at 46 V and 30 eV respectively, whereas
for IS the optimized cone voltage and collision energy
was 36 V and 22 eV respectively. The MS spectra (parent
ions) and MS/MS spectra (product ions) of linifanib and
IS are shown in Figure 2.
Optimization of chromatographic conditions
Several other RTKs (gefitanib, crazotinib and sunitinib)
were tested initially for the selection of appropriate IS.
Finally sunitinib was chosen due to its similarity in
chemical structure and polarity with linifanib and also
high recovery. Binary mixture of volatile buffers (e.g. am-
monium acetate and formate) and polar organic solvent
like acetonitrile and methanol comprises the majority of
mobile phase utilized for liquid chromatography tandemmass spectroscopy and are striking for use due to their
miscibility, low viscosity, ability to produce good chro-
matographic peak shape and compatibility with MS/MS
detection. So the feasibility of different compositions of
acetonitrile or methanol with ammonium acetate were
tried for separation of the analyte and IS with altered
flow-rates (in the range of 0.2–0.4 mL/min) on BEH™
C18 column (50 × 2.1 mm, i.d. 1.7 μm).The best peak
resolution along with high sensitivity was achieved with
an isocratic elution by a mobile phase comprising of
acetonitrile: 10 mM ammonium acetate (60:40) at a
flow-rate of 0.3 mL/min.
Optimization of sample processing
Clean samples are essential to minimize ion suppression
and matrix effect in bioanalytical method. For its simpli-
city, protein precipitation was investigated as the first
option for sample preparation. Phospholipids present in
plasma are considered as one of the most significant
matrixes interferences encounter in protein preparation
methodologies [19]. Due to ease and compatibility with
mobile phase, protein precipitation using acetonitrile and
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tried. Acidification of plasma by formic acid followed by
protein precipitation by acetonitrile produced maximum
recovery and therefore used for sample preparation.
Method validation
Selectivity
No peaks (≥20% in comparison to the spiked LLOQ
and ≥5% in comparison to IS) were detected in blank
plasma (obtained from different rats) at the corresponding
retention time of linifanib and IS. This indicates that the
method looks to be selective enough for quantification of
linifanib. Representative MRM chromatograms of linifanib
and IS for blank plasma (showing no significant interfer-
ence at the retention time of the analyte and IS), plasma
spiked at LLOQ level and at 1 h after administration of
linifanib are shown in Figure 3.
Linearity and lower limit of quantification
The linearity was calculated by weighted least squares
regression analysis (1/X2) of analyte/IS peak area ratios
versus analyte concentration. The method was found to
be linear in the range of 0.40-500 ng/mL for linifanib in
rat plasma. The correlation coefficients (r2) were found
to be consistently ≥0.996 during the course of validation.
The lowest point on the standard curve was accepted as
LLOQ (0.40 ng/mL) for this assay.
Precision and accuracy
Accuracy and precision were calculated based on three
batches of the four QC samples. The intra- and inter-day
precision values were ≤ 10.6 and ≤ 10.4 respectively. Like-
wise the intra- and inter-day accuracies were in the range
of 90.9–108.9 and 92.8 – 106.8%, respectively (Table 1).
The precision values should not exceed ±15% and accur-
acy was required to be within ±15% (20% for LOQ QC).
Recovery and matrix effects
The extraction efficiency of the method was determined
by the percentage recoveries of linifanib obtained from
plasma at three different QC concentration levels (1.28,
42.5 and 425 ng/mL) and IS (100 ng/mL). The mean
percentage recovery was 71.8 ± 9.2% for linifanib and 75.1%
for IS (Table 2). These results indicate that the recovery of
linifanib using protein precipitation method by acetonitrile
was satisfactory, consistent and concentration independent.
The matrix effects were examined to assess the possibility
of the ionization suppression or enhancement. The data
for matrix effects were in the range of ±15%, indicating
no significant matrix effects.
Stability and dilution integrity
The stability results of freeze–thaw, post preparative,
short-term and long-term are summarized in Table 3.Results indicate that linifanib spiked into rat plasma was
stable during three freeze-thaw cycle, at least 6.0 h at
room temperature, 48 h in autosampler and up to 30 days
at around −80°C. The stock solutions and working stand-
ard of linifanib and IS were also stable for 15 days at
refrigerator temperature (below 10°C) and for 12 h at
room temperature. In dilution integrity study, the percent-
age accuracy of two and four times diluted samples were
98.9 and 100.7% of the nominal concentration for linifanib.
These results concluded that the dilution of the concen-
trated plasma sample up to four times maintains legibility
and integrity of linifanib concentration.
Pharmacokinetic study in rats
The developed method was applied to analyse the linifanib
concentration in the rats plasma After oral administration
of linifanib (5 mg/kg), mean peak plasma concentration of
55.09 ng/mL were achieved after 2.5 hrs. The mean
AUC0-8h was 232.05 ng.hr/mL and average t½ and Kel of
6.67 h and 0.10 hr-1 respectively. The mean plasma
concentration versus time profile of linifanib in rats is
shown in Figure 4.
Conclusion
A selective and sensitive UHPLC-MS/MS method was
developed and validated for the determination of linifanib
(ABT-869) in rat plasma for the first time. Compared to
previous reported method in human plasma, this method
is more sensitive, rapid and simple in terms of chromato-
graphic separation. The developed method was applied to
determine the plasma concentrations of linifanib in rats in
a pilot pharmacokinetic study. The simplicity and broad
calibration range of this assay can be applicable to further
characterize linifanib in drug development.
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